Clinical Trial Update: Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating IBI308 with bevacizumab plus pemetrexed and carboplatin followed by surgery in unresectable stage III non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• IBI308 (IBI308)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lung Cancer Stage III | Phase 2 | Status: RECRUITING